Medical News

RSS

FDA approves St. Jude Medical's Trifecta valve for stented aortic valve replacement

St. Jude Medical, Inc., a global medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) approval for its Trifecta™ valve. The valve, a clinically-proven replacement for diseased, damaged or malfunctioning aortic heart valves, mimics the flow of a natural, healthy heart and represents a significant new product in the pericardial aortic stented tissue valve market.

21 Apr 2011

Genetically modified mosquitoes tested to prevent spread of malaria: Study

According to the latest study in the journal Nature, researchers from Imperial College London and the University of Washington, Seattle found that after making specific genetic changes to a few mosquitoes and then allowing them to breed could eventually dramatically reduce the spread of the deadly disease malaria.

20 Apr 2011

Brain trauma helped by nutrition

According to a report by the Institute of Medicine, military personnel who suffer traumatic brain injury need to be fed adequately and immediately to reduce the severity of trauma and improve their chance of survival. This finding has implications for people sustaining head injuries in other situations, such as sports and traffic accidents.

20 Apr 2011

$2.3 million of malaria medicines stolen

According to the Global Fund to Fight AIDS, Tuberculosis and Malaria, malaria medications valued at almost $2.3 million may have been stolen from government-run distribution centers in Africa and other locations.

20 Apr 2011

America’s best loved drugs: Report

According to the latest report from consulting firm IMS Health, Americans are consuming a lot of prescription drugs. And they seem especially fond of those to lower their cholesterol, relieve heartburn, aid in depressive disorders and lessen pain. Overall, however, their spending on such drugs is slowing.

20 Apr 2011

Stepped up measures to tack rising painkiller abuse

Prescription drug abuse is one of the largest problems in the country say experts and according to White House drug Czar Gil Kerlikowske, the Congress must require special training for doctors and other health care workers before they are allowed to prescribe powerful drugs such as OxyContin.

20 Apr 2011

Enrollment begins in ‘National Health and Aging Trends’ study

The National Health and Aging Trends Study (NHATS), led by researchers at the Johns Hopkins Bloomberg School of Public Health, will begin enrolling study participants to examine how current and future aging populations can lead fuller, healthier lives. The study, which begins data collection on May 1, 2011, is supported by the National Institute on Aging and is designed to help researchers understand changes in health and functioning among seniors, as well as the social and economic consequences of health and aging for individuals, families and society.

20 Apr 2011

Anavex: First-in-human dosing cmmenced in ANAVEX 2-73 clinical trial for Alzheimer’s

Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that the first healthy human volunteers have been initially dosed in its Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease. “We are pleased that the first volunteers have been dosed with the study drug, according to the study protocol, and no adverse events have been recorded post dosing to date," said Dr. Ozkan Yalkinoglou, Medical Director of ABX-CRO.

20 Apr 2011

Intrinsic Bioprobes launches mass spectrometry-based protein assays for in-vitro diagnostic testing

Intrinsic Bioprobes Inc. ("IBI") today announced the launch of its first mass spectrometry-based protein assays for in-vitro diagnostic testing. The assays for beta-2-microglobulin, cystatin C, and retinol binding protein are performed on IBI's MASSAY® platform at the CLIA-certified and College of American Pathology (CAP) accredited diagnostic laboratory of the Institute of Genomics Medicine, UMDNJ-New Jersey Medical School.

20 Apr 2011

Gilead, MicroDose enter collaboration for inhalable small molecule antiviral fusion inhibitor MDT-637

Gilead Sciences, Inc. and MicroDose Therapeutx, Inc. today announced that the companies have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of MDT-637, MicroDose's inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV).

20 Apr 2011

InfraReDx's LipiScan IVUS Coronary Imaging System receives European CE Mark approval

InfraReDx, Inc., a medical device company providing intelligent cardiovascular diagnostic imaging technologies, today announced it has received CE Mark approval to begin commercialization of the LipiScan™ IVUS Coronary Imaging System throughout Europe.

20 Apr 2011

Prism Pharmaceuticals to be acquired by Baxter

Ligand Pharmaceuticals Incorporated announced that its partner Prism Pharmaceuticals has entered into a definitive agreement to be acquired by Baxter International Inc.. Prism Pharmaceuticals recently received FDA approval for Nexterone®, an antiarrhythmic agent which Ligand (through its CyDex Pharmaceuticals subsidiary) originally developed with its patented Captisol® formulation technology and licensed to Prism in 2006.

From Baxter International Inc. 20 Apr 2011

Roche's cobas HPV Test receives FDA approval for cervical cancer screening

Roche announced today that the U.S. Food and Drug Administration (FDA) has approved the cobas HPV (Human Papillomavirus) Test which identifies women at highest risk for developing cervical cancer. This test will help physicians make early, more accurate decisions about patient care, which may prevent many women from developing this deadly disease.

From Roche Sequencing and Life Science 20 Apr 2011

Spacelabs Healthcare introduces XPREZZON patient monitoring solution

Spacelabs Healthcare, which decades ago pioneered medical telemetry to monitor the vital signs of orbiting astronauts, today announced the launch of XPREZZON, a patient monitoring solution that delivers innovative technology and design to shape the new age of care for clinicians and patients alike.

20 Apr 2011

Florida Hospital uses flexible surgery instruments from Apollo Endosurgery for stomach tumor extraction

Florida Hospital Celebration Health announced this week the use of a new class of flexible surgical instruments created by Apollo Endosurgery®, to remove a stomach tumor and extract it through the patient's mouth. Following the two-hour surgery, the patient spent one night in the hospital and was prescribed Acetaminophen for pain.

20 Apr 2011

Stealth Peptides launches mitochondrion targeting compound Bendavia at Experimental Biology 2011

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative mitochondrial therapies, introduced its lead clinical candidate, Bendavia™, a novel compound that targets the mitochondrion, during multiple scientific sessions of the Experimental Biology 2011 meeting.

20 Apr 2011

Treatment for Bipolar Disorder now available in Nova Scotia Formulary

The Nova Scotia Department of Health and Wellness has approved the listing of LITHMAX (Lithium Carbonate Sustained-Release 300mg Tablets) in the Nova Scotia Formulary, effective April 19th, 2011. This announcement comes as welcome news to patients in need of the sustained-release formulation of Lithium Carbonate who require help to pay for prescribed medications.

20 Apr 2011

Aduro raises $19.25 million through Series B equity financing

Aduro BioTech, a clinical-stage immunotherapy company, announced today that it has completed its Series B equity financing from a combination of current investors and Morningside Ventures, bringing the total capital secured in this round to $19.25 million. In addition, Ms. Stephanie O'Brien, who represents Morningside, has joined Aduro's Board of Directors.

20 Apr 2011

Ludwig Institute demonstrates ability of DAVANAT to enhance efficacy of T-lymphocytes to kill tumor cells

Pro-Pharmaceuticals, Inc. today announced that the Brussels Branch of the Ludwig Institute for Cancer Research demonstrated the ability of GM-CT-01 (DAVANAT®) to enhance the ability of tumor-specific T-lymphocytes to kill tumor cells.

20 Apr 2011

ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

ARIAD Pharmaceuticals, Inc. today announced execution of three exclusive out-license agreements for separate aspects of its ARGENT™ cell-signaling regulation technology.

20 Apr 2011

Medical News

FDA approves St. Jude Medical's Trifecta valve for stented aortic valve replacement

Genetically modified mosquitoes tested to prevent spread of malaria: Study

Brain trauma helped by nutrition

$2.3 million of malaria medicines stolen

America’s best loved drugs: Report

Stepped up measures to tack rising painkiller abuse

Enrollment begins in ‘National Health and Aging Trends’ study

Anavex: First-in-human dosing cmmenced in ANAVEX 2-73 clinical trial for Alzheimer’s

Intrinsic Bioprobes launches mass spectrometry-based protein assays for in-vitro diagnostic testing

Gilead, MicroDose enter collaboration for inhalable small molecule antiviral fusion inhibitor MDT-637

InfraReDx's LipiScan IVUS Coronary Imaging System receives European CE Mark approval

Prism Pharmaceuticals to be acquired by Baxter

Roche's cobas HPV Test receives FDA approval for cervical cancer screening

Spacelabs Healthcare introduces XPREZZON patient monitoring solution

Florida Hospital uses flexible surgery instruments from Apollo Endosurgery for stomach tumor extraction

Stealth Peptides launches mitochondrion targeting compound Bendavia at Experimental Biology 2011

Treatment for Bipolar Disorder now available in Nova Scotia Formulary

Aduro raises $19.25 million through Series B equity financing

Ludwig Institute demonstrates ability of DAVANAT to enhance efficacy of T-lymphocytes to kill tumor cells

ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

A new method to measure intracellular water in biological systems

Obesity, GLP-1s, and metabolic care

Automation in cell-based workflows

Latest News